{"url_path":"/sec/igc/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-001885-index.html","accession_number":"0001185185-26-001885","cik":"0001326205","ticker":"IGC","issuer_name":"IGC Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-001885-index.html","primary_entity_key":"0001326205","primary_entity_name":"IGC Pharma, Inc."},"word_count":425,"has_tables":true,"body_markdown":"**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549** \n\n \n\n \n\n \n\n**FORM\n10-Q**\n\n \n\n \n\n \n\n☑  **Quarterly\nreport pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐\n**Transition** **report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**Commission\nfile number: 001-32830**\n\n** **\n\n** **\n\n** **\n\n**IGC\nPHARMA, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Maryland**   **20-2760393**\n\n(State or other jurisdiction of\n\nincorporation or organization)   (I.R.S. Employer\nIdentification No.)\n\n     \n\n**10224 Falls Road, Potomac, Maryland**   **20854**\n\n(Address of principal executive offices)   (Zip Code)\n\n \n\n**(301)\n983-0998**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**   **Trading** **symbol(s)**   **Name of each exchange on which** **registered**\n\nCommon Stock, par value $0.0001 per share   IGC   NYSE American LLC\n\n \n\nIndicate\nby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). ☑  Yes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐   Accelerated filer ☐\n\nNon-accelerated filer ☑   Smaller reporting company ☑\n\n    Emerging growth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑\nNo\n\n \n\n100,091,317\nshares of our common stock were outstanding as of April 27, 2026.\n\n \n\n|\nMarch 31, 2026, Form 10-Q\n\n \n\n \n\n \n\n \n\n \n\n \n\n**IGC\nPHARMA, INC.**\n\n**FORM\n10-Q**\n\n**FOR\nTHE QUARTERLY PERIOD ENDED MARCH 31, 2026**\n\n \n\n**Table\nof Contents**\n\n \n\n \n \n**Page**\n\n[**PART I. FINANCIAL INFORMATION**](#a_001)"}